Presentation is loading. Please wait.

Presentation is loading. Please wait.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.

Published byDerrick Hall Modified over 6 years ago

Similar presentations

Presentation on theme: "Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7."— Presentation transcript:

1 Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials  Kristian Reich, MD, Craig Leonardi, MD, PC, Richard G. Langley, MD, FRCPC, Richard B. Warren, MBChB (Hons), PhD, Hervé Bachelez, MD, PhD, Ricardo Romiti, MD, Mamitaro Ohtsuki, MD, PhD, Wen Xu, PhD, Nayan Acharya, MBBS, MRCP, MFPM, Kathleen Solotkin, MSN, Jean-Frederic Colombel, MD, Dana S. Hardin, MD  Journal of the American Academy of Dermatology  Volume 76, Issue 3, Pages e2 (March 2017) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Patient disposition. aPatient was determined to have a Hx of CD (not captured in the clinical database) by a gastroenterologist after the definitive event. bPatient was on 80-mg IXE Q4W during the induction period (after a 160-mg starting dose) then discontinued because of pregnancy and–69 days after discontinuing treatment–reported a flare of UC. CD, Crohn's disease; DC, discontinued; ETN, etanercept; Hx, history; IBD, inflammatory bowel disease; IXE, ixekizumab; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; SAE, serious adverse event; TEAE, treatment-emergent adverse event; UC, ulcerative colitis. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Supplemental Fig 1 Crohn's disease. Treatment sequence and exposure days before the first event. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Supplemental Fig 2 Ulcerative colitis. Treatment sequence and exposure days before the first event. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7."

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
A girl with a solitary red bulla

A girl with a solitary red bulla
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment  Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,

Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment  Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort  Shelley.

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort  Shelley.
Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry  David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry  David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Similar presentations

Ads by Google